In bladder cancers, numerous gene alterations have been reported in a fare percentage of tumor samples including PTEN deletions, mutations of FGFR3, TP53, RAS or RAF or mutations of several key factors of the PI3K/Akt/mTOR signalling pathway (reviewed in [16]). The gene discussed is MTOR; the disease is urinary bladder carcinoma.